Clinical Trials/NCT00591396

NCT00591396CompletedPhase 1

A Phase I Trial of ZIO-101 in Solid Tumors: Protocol # SGL1002

Alaunos Therapeutics0 sites40 target enrollmentStarted: July 2005Last updated: July 19, 2012

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 1
Status: Completed
Sponsor: Alaunos Therapeutics
Enrollment: 40
Primary Endpoint: toxicities

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

A Phase I Trial of ZIO-101 (Darinaparsin) in Solid Tumors

Study Design

Study Type: Interventional
Allocation: Non Randomized
Intervention Model: Single Group
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Arms & Interventions

Single Arm

Experimental

Intervention: ZIO-101 (Darinaparsin) (Drug)

Outcomes

Primary Outcomes

toxicities

Time Frame: 6 months

Secondary Outcomes

pharmacokinetics(6 months)

Investigators

Sponsor

Alaunos Therapeutics

Sponsor Class

Industry

Responsible Party

Sponsor

Similar Trials

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's LymphomasAdvanced Cancer

NCT00591422Alaunos Therapeutics23

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and LymphomasAdvanced Solid TumorsLymphomas

NCT00592163Alaunos Therapeutics20

A Phase I Trial of ZIO-101 in Hematologic CancersChronic Myeloproliferative DiseaseChronic Lymphoproliferative DiseasePoor-risk Myelodysplasia (MDS)Multiple MyelomaLymphomaAcute Leukemia

NCT00592046Alaunos Therapeutics12

Active, not recruiting

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCSCLC,Extensive Stage

NCT05595460RayzeBio, Inc.21

Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid TumorsAdvanced Cancer

NCT00608803Alaunos Therapeutics30